Abcam, ab259014, Human OAS2 knockout A549 cell lysate

Size: 1Kit
OAS2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-OAS2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Oligoadenylate synthetase 2 (OAS2) is also known as OAS2A and OAS2LLC. It belongs to the 2'-5' oligoadenylate synthase family and possesses a mass of approximately 71 kDa. OAS2 is expressed in various tissues with higher levels noted in the liver and immune cells. Its mechanical function involves the synthesis of 2'-5' linked oligoadenylates (2-5A) upon activation by double-stranded RNA a byproduct of viral infections signalling for the degradation of viral RNA.
Biological function summary
OAS2 is essential in the innate immune response against viral infections. It forms part of a protein complex that activates RNase L an enzyme responsible for degrading viral and cellular RNA thereby limiting viral replication. By doing this OAS2 helps control viral proliferation during the early phases of infection contributing to the host's antiviral defense mechanisms.
Pathways
OAS2 functions in the antiviral pathway related to the innate immune response. It closely associates with the interferon signaling pathway initiating a cascade of reactions that enhance the immune response. RNase L and OAS1 are important proteins related to OAS2 in this pathway. Both proteins synergistically work to recognize and respond to viral infections ensuring an effective and timely immune response.
Researchers have linked OAS2 to diseases such as viral hepatitis and autoimmune disorders like SLE (Systemic Lupus Erythematosus). In viral hepatitis OAS2 plays a role in limiting the replication of hepatitis viruses and studies have observed its interaction with proteins like interleukin-6 (IL-6) within the context of SLE. The aberrant activation or regulation of OAS2 might contribute to disease pathogenesis or severity making it a potential target for therapeutic intervention.